



**SDI Review Form 1.6**

Journal Name:	<b><u>Journal of Cancer and Tumor International</u></b>
Manuscript Number:	<b>2015_JCTI_17780</b>
Title of the Manuscript:	<b>Potential Antineoplastic Structural Variations of Uracil Mustard (Uramustine) Retaining Cytotoxic Activity and Drug-likeness Suitable for Oral Administration</b>
Type of the Article	<b>Original Research Article</b>

**General guideline for Peer Review process:**

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



**SDI Review Form 1.6**

**PART 1: Review Comments**

	<b>Reviewer's comment</b>	<b>Author's comment</b> (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b><u>Compulsory</u></b> REVISION comments	<p><b>Potential Antineoplastic Structural Variations of Uracil Mustard (Uramustine) Retaining Cytotoxic Activity and Drug-likeness Suitable for Oral Administration</b></p> <p>The title of the article is excellent. It carries good informative messages to the physicians who deal with this drug.</p> <ul style="list-style-type: none"> <li>• There are some grammatical mistakes in the paper, results in ambiguity of meaning of the sentences.</li> <li>• The spelling should be checked.</li> <li>• It necessary to quote the list of abbreviations.</li> <li>• As it is a research study, author's contributions are necessary to mentioned.</li> <li>• In the result, as a test of significance, rho test and students't test not done, please clarify.</li> <li>• As it is a vast research, it is mandatory to notice source of funding.</li> <li>• Was permission taken from the ethical committee?</li> <li>• Were the patient followed –up? How long?</li> <li>• What were the parameters for follow-up of patients to see the effects of drugs?</li> <li>• Conflicts of interest are not mentioned.</li> <li>• In conclusion, details of the paper are written. It can be added in the discussion chapter with appropriate references.</li> <li>• What are the further suggestions of this study?</li> </ul>	



**SDI Review Form 1.6**

	<ul style="list-style-type: none"> <li>The conclusion must be pin-point which can help the readers to get the appropriate messages of the paper.</li> </ul> <p><b>Ethical issues-:</b> <b>Yes, It carries good informative messages to the physicians who deal with this drug.</b></p>	
<b><u>Minor</u></b> REVISION comments		
<b><u>Optional/General</u></b> comments		

**Reviewer Details:**

Name:	<b>Golam Hafiz</b>
Department, University & Country	<b>Department of Pediatric Hematology and Oncology Bangabandhu Sheikh Mujib Medical University, Bangladesh</b>